[
  {
    "ts": null,
    "headline": "Assessing Medtronic’s (MDT) Valuation After Its Steady 24% Year-to-Date Share Price Climb",
    "summary": "Medtronic (MDT) has quietly outperformed the broader healthcare space over the past year, and that steady climb is getting investors to revisit whether this long standing medical device leader still offers reasonable upside. See our latest analysis for Medtronic. Despite a soft patch in the last week, Medtronic’s roughly 24 percent year to date share price return and solid one year total shareholder return near 25 percent point to steady, not euphoric, momentum as investors warm to its...",
    "url": "https://finnhub.io/api/news?id=4857c2712220afc75a8126ead6feefa2dd581f025f4bcf1802ea8982c1dac4b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765534049,
      "headline": "Assessing Medtronic’s (MDT) Valuation After Its Steady 24% Year-to-Date Share Price Climb",
      "id": 137767060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic (MDT) has quietly outperformed the broader healthcare space over the past year, and that steady climb is getting investors to revisit whether this long standing medical device leader still offers reasonable upside. See our latest analysis for Medtronic. Despite a soft patch in the last week, Medtronic’s roughly 24 percent year to date share price return and solid one year total shareholder return near 25 percent point to steady, not euphoric, momentum as investors warm to its...",
      "url": "https://finnhub.io/api/news?id=4857c2712220afc75a8126ead6feefa2dd581f025f4bcf1802ea8982c1dac4b7"
    }
  },
  {
    "ts": null,
    "headline": "Did FDA-Approved Hugo Robot and New Diabetes Tech Just Shift Medtronic's (MDT) Investment Narrative?",
    "summary": "In early December 2025, Medtronic’s board approved a US$0.71 per-share cash dividend for the third quarter of fiscal 2026, payable on January 16, 2026, and the company secured FDA clearance for its Hugo robotic-assisted surgery system in urologic procedures while launching its MiniMed 780G system with Abbott’s Instinct sensor across the U.S. Together, these developments highlight how Medtronic is pairing a long-running dividend growth record with fresh momentum in robotics and diabetes...",
    "url": "https://finnhub.io/api/news?id=f098d5d3d513abc12e06f79ae4afead26a58c9ed54908a5cf64abd6be78f6a10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765530778,
      "headline": "Did FDA-Approved Hugo Robot and New Diabetes Tech Just Shift Medtronic's (MDT) Investment Narrative?",
      "id": 137766985,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "In early December 2025, Medtronic’s board approved a US$0.71 per-share cash dividend for the third quarter of fiscal 2026, payable on January 16, 2026, and the company secured FDA clearance for its Hugo robotic-assisted surgery system in urologic procedures while launching its MiniMed 780G system with Abbott’s Instinct sensor across the U.S. Together, these developments highlight how Medtronic is pairing a long-running dividend growth record with fresh momentum in robotics and diabetes...",
      "url": "https://finnhub.io/api/news?id=f098d5d3d513abc12e06f79ae4afead26a58c9ed54908a5cf64abd6be78f6a10"
    }
  }
]